Deok‐Bog Moon
YOU?
Author Swipe
View article: Donor-to-recipient sex match status has no prognostic effect on long-term survival following liver transplantation: a retrospective observational study
Donor-to-recipient sex match status has no prognostic effect on long-term survival following liver transplantation: a retrospective observational study Open
Donor-to-recipient sex match status does not significantly affect post-transplant patient survival or HCC prognosis after LDLT or DDLT.
View article: Long-Term Prognostic Significance of TACE-Induced Complete Pathological Response in Patients with Hepatocellular Carcinoma Who Have Undergone Liver Transplantation
Long-Term Prognostic Significance of TACE-Induced Complete Pathological Response in Patients with Hepatocellular Carcinoma Who Have Undergone Liver Transplantation Open
BACKGROUND Complete pathological response (CPR) after transcatheter arterial chemoembolization (TACE) is associated with improved posttransplant outcomes in patients with hepatocellular carcinoma (HCC). This study evaluated the prognostic …
View article: Long-Term Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma After Liver Transplantation in Patients with or without Concurrent Hepatocellular Carcinoma
Long-Term Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma After Liver Transplantation in Patients with or without Concurrent Hepatocellular Carcinoma Open
BACKGROUND Combined hepatocellular carcinoma-cholangiocarcinoma (CHC), a rare disease, is usually an incidental diagnosis after liver transplantation (LT). In this study, we investigated the long-term post-transplant outcomes of CHC patien…
View article: Post-Transplant Outcomes in Patients with Previously Treated Extrahepatic Malignancies Undergoing Living Donor Liver Transplantation
Post-Transplant Outcomes in Patients with Previously Treated Extrahepatic Malignancies Undergoing Living Donor Liver Transplantation Open
BACKGROUND Post-transplant outcomes were analyzed in adult patients with primary extrahepatic malignancies (EHM) who underwent living donor liver transplantation (LDLT). Few studies to date have analyzed post-transplant outcomes in adult p…
View article: Long-Term Outcomes of Left Renal Vein Ligation in Living Donor Liver Transplantation: A 20-Year Study
Long-Term Outcomes of Left Renal Vein Ligation in Living Donor Liver Transplantation: A 20-Year Study Open
BACKGROUND Persistence of large spontaneous splenorenal shunt (SSRS) can result in graft failure in adult living donor liver transplantation (LDLT) due to portal flow steal; thus, it is necessary to block SSRS to ensure sufficient portal b…
View article: Limited survival benefit of preoperative transarterial chemoembolization in huge hepatocellular carcinoma due to the prognostic impact of satellite nodules: a retrospective cohort study
Limited survival benefit of preoperative transarterial chemoembolization in huge hepatocellular carcinoma due to the prognostic impact of satellite nodules: a retrospective cohort study Open
Preoperative TACE for huge HCC was associated with reduced MVI but did not improve RFS and OS. Survival outcomes were more significantly influenced by SN, suggesting that upfront hepatectomy without TACE should be prioritized.
View article: Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial
Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial Open
Regorafenib plus nivolumab (RegoNivo) combination has shown promising anti-cancer activity in multiple cancer types. REBNOBATE trial is a single-arm multicenter phase 2 trial of first-line RegoNivo in patients (pts) with uHCC (NCT04310709)…
View article: Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial
Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial Open
Regorafenib plus nivolumab (RegoNivo) combination has shown promising anti-cancer activity in multiple cancer types. REBNOBATE trial is a single-arm multicenter phase 2 trial of first-line RegoNivo in patients (pts) with uHCC (NCT04310709)…
View article: Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial
Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial Open
Regorafenib plus nivolumab (RegoNivo) combination has shown promising anti-cancer activity in multiple cancer types. REBNOBATE trial is a single-arm multicenter phase 2 trial of first-line RegoNivo in patients (pts) with uHCC (NCT04310709)…
View article: Outcomes of liver resection and transarterial chemoembolization in patients with multinodular BCLC-A hepatocellular carcinoma
Outcomes of liver resection and transarterial chemoembolization in patients with multinodular BCLC-A hepatocellular carcinoma Open
Backgrounds/Aims: This study aimed to compare the outcomes of liver resection (LR) and transarterial chemoembolization (TACE) in patients with multinodular hepatocellular carcinoma (HCC) within the Milan criteria who were not eligible for …
View article: No Prognostic Impact of Graft-to-Recipient Weight Ratio on Hepatocellular Carcinoma Recurrence Following Living Donor Liver Transplantation
No Prognostic Impact of Graft-to-Recipient Weight Ratio on Hepatocellular Carcinoma Recurrence Following Living Donor Liver Transplantation Open
BACKGROUND The effects of a low graft-to-recipient weight ratio (GRWR) on the prognosis of patients with hepatocellular carcinoma (HCC) are unclear. The present study examined whether the GRWR had an impact on the rate of HCC recurrence fo…
View article: Clinical significance and outcomes of adult living donor liver transplantation for acute liver failure: a retrospective cohort study based on 15-year single-center experience
Clinical significance and outcomes of adult living donor liver transplantation for acute liver failure: a retrospective cohort study based on 15-year single-center experience Open
LDLT is feasible for acute liver failure when organs from deceased donors are not available.
View article: Outcomes of six-thousand living donor liver transplantation: a 30-year journey in a high-volume single center
Outcomes of six-thousand living donor liver transplantation: a 30-year journey in a high-volume single center Open
Asan Medical Center received global attention in 1999 with the first living donor liver transplantation (LDLT) using a modified right lobe graft.This landmark operation played a major role in improving recipient outcomes while ensuring don…
View article: Graft-to-recipient weight ratio does not affect hepatocellular carcinoma recurrence after living donor liver transplantation
Graft-to-recipient weight ratio does not affect hepatocellular carcinoma recurrence after living donor liver transplantation Open
Doyoung Lee, Shin Hwang, Chul-soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Young-In Yoon, Woo-Hyoung Kang. Korean J Transplant 2023;37:275. https://doi.org/10.4285/ATW2023.F-8882
View article: Predictors of postrecurrence survival in hepatocellular carcinoma patients after living donor liver transplantation
Predictors of postrecurrence survival in hepatocellular carcinoma patients after living donor liver transplantation Open
Min-Ha Choi, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Young-In Yoon, Woo-Hyoung Kang. Korean J Transplant 2023;37:122. https://doi.org/10.4285/ATW2023.F-7052
View article: Donor sex and donor-recipient sex disparity do not affect hepatocellular carcinoma recurrence after living donor liver transplantation
Donor sex and donor-recipient sex disparity do not affect hepatocellular carcinoma recurrence after living donor liver transplantation Open
Background:Studies have yielded contradictory results on whether donor sex and donor-recipient sex disparity affect hepatocellular carcinoma (HCC) recurrence after living donor liver transplantation (LDLT).The present study assessed whethe…
View article: Recipient blood group do not affect hepatocellular carcinoma recurrence after living donor liver transplantation
Recipient blood group do not affect hepatocellular carcinoma recurrence after living donor liver transplantation Open
Hyo Jung Ko, Shin Hwang, Gi-Won Won, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Dong-Hwan Jung, Gil-Chun Park, Young-In Yoon, Woo-Hyoung Kang. Korean J Transplant 2023;37:7. https://doi.org/10.4285/ATW2023.F-5660
View article: Biliary stricture of duct-to-duct anastomosis in living donor liver transplantation for hepatocellular carcinoma previously treated with external beam radiotherapy
Biliary stricture of duct-to-duct anastomosis in living donor liver transplantation for hepatocellular carcinoma previously treated with external beam radiotherapy Open
Background: External beam radiotherapy (EBRT) has been proven to provide acceptable oncologic outcomes in selected patients with hepatocellular carcinoma (HCC) followed by adult living donor liver transplantation (LDLT).The study aims to e…
View article: The clinical outcome of hepatic artery dissection after living donor liver transplantation in a high volume center
The clinical outcome of hepatic artery dissection after living donor liver transplantation in a high volume center Open
Background: Hepatic artery dissection (HAD) is an uncommon complication of living donor liver transplantation (LDLT) and is associated with hepatic artery thrombosis (HAT).Since the incidence of HAD is low, clinical outcomes have not been …
View article: Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial
Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial Open
In this phase 2 REBNOBATE trial, we evaluated regorafenib-nivolumab as front-line treatment for unresectable hepatocellular carcinoma (uHCC). Patients ( n = 42) received nivolumab 480 mg every 4 weeks, and regorafenib 80 mg daily (3-weeks …
View article: Efficacy and safety of adhesion barrier in living-donor liver transplantation with right liver graft to prevent delayed gastric emptying
Efficacy and safety of adhesion barrier in living-donor liver transplantation with right liver graft to prevent delayed gastric emptying Open
Sang-Hoon KIM, Dong-Hwan JUNG*, Sung-Gyu LEE, Shin HWANG, Chul-Soo AHN, Ki-Hun KIM, Deok-Bog MOON, Tae-Yong HA, Gi-Won SONG, Gil-Chun PARK, Young-In YOON, Woo-Hyung KANG, Hwui-Dong CHO, Su-Min HA, Byeong-Gon NA, Minjae KIM, Sung-Min KIM, G…
View article: Tips for outflow reconstruction in salvage or Re-LDLT
Tips for outflow reconstruction in salvage or Re-LDLT Open
LV-SY
View article: Technical feasibility and outcome of salvage living donor liver transplantation after major hepatectomy
Technical feasibility and outcome of salvage living donor liver transplantation after major hepatectomy Open
Background: Salvage living donor liver transplantation (LDLT) is technically challenging due to adhesions caused by previous liver resection (LR) in addition to the inherent difficulties short vasculo-biliary stumps and co-existing vasculo…
View article: Favorable prognostic factors for survival outcomes of hepatocellular carcinoma with portal vein tumor thrombosis after hepatectomy
Favorable prognostic factors for survival outcomes of hepatocellular carcinoma with portal vein tumor thrombosis after hepatectomy Open
Sang-Hoon KIM, Deok-Bog MOON*, Yo-Han PARK, Sung-Gyu LEE, Ki-Hun KIM, Shin HWANG, Chul-Soo AHN, Tae-Yong HA, Gi-Won SONG, Dong-Hwan JUNG, Gil-Chun PARK, Minjae KIM, Byeong-Gon NA, Geunhyeok YANG, Sung Min KIM, Rak-kyun OH. Ann Hepatobiliar…
View article: Outcomes of adult living donor liver transplantation for acute liver failure: A 15-year experience in a single center
Outcomes of adult living donor liver transplantation for acute liver failure: A 15-year experience in a single center Open
Geunhyeok YANG, Young-In YOON*, Deok-Bog MOON, Dong-Hwan JUNG, Gi-Won SONG, Tae-Yong HA, Gil-Chun PARK, Rak-kyun OH, Hyo Jung KO, Sung-Gyu LEE. Ann Hepatobiliary Pancreat Surg 2023;27:S204. https://doi.org/10.14701/ahbps.2023S1.LV-PP-6-4
View article: Long-term outcomes of liver transplantation in hepatocellular carcinoma patients with portal vein tumor thrombosis after downstaging
Long-term outcomes of liver transplantation in hepatocellular carcinoma patients with portal vein tumor thrombosis after downstaging Open
Sang-Hoon KIM, Deok-Bog MOON*, Sung-Gyu LEE, Hwang SHIN, Ki-Hun KIM, Chul-Soo AHN, Tae-Yong HA, Gi-Won SONG, Dong-Hwan JUNG, Gil-Chun PARK, Young-In YOON, Woo-Hyoung KANG, Hwui-Dong CHO, Su-Min HA, Byeong-Gon NA, Minjae KIM, Sung-Min KIM, …
View article: Rescue therapy using transjugular intrahepatic portosystemic shunt for sudden-onset portal vein thrombosis-associated ascites after living donor liver transplantation
Rescue therapy using transjugular intrahepatic portosystemic shunt for sudden-onset portal vein thrombosis-associated ascites after living donor liver transplantation Open
Sudden-onset portal vein (PV) thrombosis can result in refractory massive ascites.Transjugular intrahepatic portosystemic shunt (TIPS) can be a bridge or rescue therapy for the restoration of portal blood flow and control of ascites.We pre…